GRAIL (GRAL) Is Down 6.5% After FDA Sets Galleri PMA Panel Review – Has The Bull Case Changed?
- GRAIL announced that the FDA’s Molecular and Clinical Genetics Panel will meet on September 23, 2026, to review the Premarket Approval application for its Galleri multi-cancer early detection blood test, which targets cancer-specific methylation patterns and is intended to complement existing screening methods.
- This review marks a major regulatory inflection point for what GRAIL describes as the only multi-cancer early detection test backed by large interventional and randomized, controlled trials in intended use populations, supported by data from more than 95,000 participants across PATHFINDER 2 and NHS-Galleri.
- With the upcoming advisory committee review of Galleri’s Premarket Approval, we’ll assess how this regulatory…
Source link
